XML 39 R29.htm IDEA: XBRL DOCUMENT v3.20.2
Financial Instruments and Fair Value Measurements (Tables)
 9 Months Ended
Sep. 25, 2020
Fair Value Disclosures [Abstract]  
Schedule of Fair Value of Assets and Liabilities Measured on a Recurring Basis
The following tables provide a summary of the significant assets and liabilities that are measured at fair value on a recurring basis at the end of each period:

September 25,
2020
Quoted Prices in Active Markets for Identical Assets
(Level 1)
Significant Other Observable Inputs
(Level 2)
Significant Unobservable Inputs
(Level 3)
Assets:
Debt and equity securities held in rabbi trusts
$31.8 $22.5 $9.3 $— 
Equity securities
28.0 28.0 — — 
$59.8 $50.5 $9.3 $— 

Liabilities:
Deferred compensation liabilities
$33.2 $— $33.2 $— 
Contingent consideration and acquired contingent liabilities
27.2 — — 27.2 
Settlement Warrants9.3 — — 9.3 

$69.7 $— $33.2 $36.5 
December 27,
2019
Quoted Prices in Active Markets for Identical Assets
(Level 1)
Significant Other Observable Inputs
(Level 2)
Significant Unobservable Inputs
(Level 3)
Assets:
Debt and equity securities held in rabbi trusts
$30.6 $21.0 $9.6 $— 
Equity securities
26.2 26.2 — — 
$56.8 $47.2 $9.6 $— 
Liabilities:
Deferred compensation liabilities
$39.2 $— $39.2 $— 
Contingent consideration and acquired contingent liabilities
69.3 — — 69.3 
Settlement Warrants43.4 — — 43.4 
$151.9 $— $39.2 $112.7 
Schedule of Reconciliation of Changes in Fair Value of Contingent Liabilities The following table summarizes the activity for contingent consideration:
Balance as of December 27, 2019$69.3 
Payments
(45.0)
Accretion expense
0.5
Fair value adjustments
2.4 
Balance as of September 25, 2020$27.2 
Schedule of Share-based Payment Awared, Warrants, Valuation Assumptions [Table Text Block] [Table Text Block]
The key assumptions used to estimate the fair value of the Settlement Warrants were as follows:
September 25,
2020		December 27, 2019
Expected share price volatility60.1 %54.4 %
Weighted-average risk-free rate0.5 %1.8 %
Expected annual dividend per share— %— %
Weighted-average expected term (in years)7.67.6
Share price$1.14 $3.45 
Schedule of Carrying Amount and Fair Value of Long-term Debt The following table presents the carrying values and estimated fair values of the Company's debt as of the end of each period:
September 25, 2020December 27, 2019
Carrying
Value		Fair
Value		Carrying
Value		Fair
Value
Level 1:
4.875% senior notes due April 2020$— $— $614.8 $480.0 
5.75% senior notes due August 2022610.3 159.8 610.3 251.0 
4.75% senior notes due April 2023133.7 19.8 133.7 53.7 
5.625% senior notes due October 2023514.7 125.5 514.7 193.2 
5.50% senior notes due April 2025387.2 93.1 387.2 135.5 
10.00% first lien senior notes due April 2025495.0 516.1 — — 
10.00% second lien senior notes due April 2025322.9 252.6 322.9 253.8 
Revolving credit facility900.0 900.0 900.0 900.0 
Level 2:
9.50% debentures due May 202210.4 4.2 10.4 5.4 
8.00% debentures due March 20234.4 1.3 4.4 2.0 
Term loan due September 20241,509.1 1,318.8 1,520.8 1,240.0 
Term loan due February 2025400.5 349.1 403.6 326.2 
Total Debt$5,288.2 $3,740.3 $5,422.8 $3,840.8 
Schedules of Concentration of Risk
The following table shows net sales attributable to distributors that accounted for 10.0% or more of the Company's total segment net sales, which excludes the one-time charge related to the Medicaid lawsuit:
Three Months EndedNine Months Ended
September 25,
2020		September 27,
2019		September 25,
2020		September 27,
2019
CuraScript, Inc.
28.1 %31.1 %27.7 %30.2 %

The following table shows accounts receivable attributable to distributors that accounted for 10.0% or more of the Company's gross accounts receivable at the end of each period:
September 25,
2020		December 27,
2019
AmerisourceBergen Corporation
26.5 %31.3 %
McKesson Corporation
18.1 15.3 
CuraScript, Inc.
13.2 12.1 

The following table shows net sales attributable to products that accounted for 10.0% or more of the Company's total segment net sales, which excludes the one-time charge related to the Medicaid lawsuit:
Three Months EndedNine Months Ended
September 25,
2020		September 27,
2019		September 25,
2020		September 27,
2019
Acthar Gel27.9 %30.9 %27.9 %30.5 %
INOmax20.3 18.4 21.2 18.1 
Ofirmev12.7 11.6 10.5 11.5